Shockwave Medical has received US Food and Drug Administration approval for its C2 coronary intravascular lithotripsy (IVL) therapy system.
This was described by CEO Doug Godshall as the “most significant achievement” for 2020 in Shockwave’s 2020 year-end sales and...






